New York, Jan 10, 2026, 03:42 EST — Market closed
- GSK ADRs closed Friday up 0.3% at $50.39; London shares slipped 0.26% to 1,886 pence
- AnaptysBio moved to dismiss part of a claim in a royalty dispute tied to GSK cancer drug Jemperli
- Investors next look to Jan 13 (J.P. Morgan healthcare conference) and Feb 4 (full-year results)
AnaptysBio said it filed a motion asking a U.S. court to dismiss part of a claim by GSK plc’s oncology unit, escalating a dispute over royalties tied to sales of cancer drug Jemperli, a PD-1 inhibitor — a kind of immunotherapy that helps the immune system attack tumours. Tesaro sued AnaptysBio in Delaware in November seeking to terminate a 2014 licence and halve royalty and milestone payments, while AnaptysBio countersued and pointed to trials involving rival PD-1 drugs including Merck’s Keytruda; the case is set for a July 14–17 trial and the court is expected to hear the motion by early March, with royalties under the licence rising to 25% on annual sales above $2.5 billion through patents expiring in 2035-36. GSK did not immediately respond to a request for comment, and its U.S.-listed shares ended Friday up 0.3% at $50.39. 1
Why it matters now: the dispute sits on top of a commercial oncology product in a class where competition is brutal, pricing is watched, and partners fight over the split when a drug starts to matter. Separately, Noetik said it signed a five-year, non-exclusive licensing deal giving GSK access to its cancer research “foundation models” — large AI models trained on biological datasets — with $50 million in upfront and near-term milestone payments and annual licensing fees on top; GSK executive Kim Branson called Noetik’s approach to generating spatial data at scale “novel”. 2
Investors get another checkpoint soon. GSK’s calendar shows management is due at the J.P. Morgan Healthcare Conference on Jan. 13 and the company will publish full-year and fourth-quarter results on Feb. 4 — dates that could draw questions on litigation exposure, oncology priorities and how hard it leans into partnerships like Noetik. 3
In London, GSK shares ended Friday down 0.26% at 1,886 pence, after trading between 1,871 and 1,896, according to historical pricing data. The stock is near its 52-week high of 1,909.5 pence, with the low at 1,242.5. 4
But there’s a simple risk: courts do what they do, and timelines slip. If Tesaro convinces the judge it can reset or end the licence terms, the royalty stream shifts; if AnaptysBio lands its claims, GSK could face a longer, noisier fight around how it backs Jemperli against bigger PD-1 rivals.
Next is the expected early-March hearing on the motion, and then GSK’s Feb. 4 results — the nearer-term catalyst likely to set the tone for GSK stock into the next session and beyond.
